Please login to the form below

Not currently logged in
Email:
Password:

Danish biopharma company wins R&D award

Zealand Pharma has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan

Zealand Pharma A/S has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan, a global growth consulting firm. Zealand Pharma is involved in the discovery and development of innovative peptide-based drugs. It has been ranked top for demonstrating technological superiority in its field through market analysis based on interviews and extensive secondary research.

"It is an honour to be recognised by Frost & Sullivan", said David Solomon, head of Zealand Pharma A/S. "The European Research & Development Award highlights our company's ongoing achievements in its path to commercialising peptide-based drugs that treat unmet medical need in the areas of diabetes, metabolism, cardiovascular disease and gastrointestinal disorders such as Crohn's disease." 

The award recognises the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.

All of Zealand's products target diseases and symptoms of significant unmet clinical need and commercial potential. 

Since 1999, Zealand's scientists have built a pipeline that includes five compounds in clinical development, three of which have been out-licensed to pharmaceutical companies, sanofi-aventis, Wyeth and Helsinn Healthcare.

18th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics